No connection

Search Results

LLY vs MNDR

LLY
Eli Lilly and Company
NEUTRAL
Price
$958.65
Market Cap
$858.01B
Sector
Healthcare
AI Confidence
85%
MNDR
Mobile-health Network Solutions
BEARISH
Price
$0.84
Market Cap
$3.1M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
LLY
41.7
MNDR
--
Forward P/E
LLY
22.78
MNDR
--
P/B Ratio
LLY
32.33
MNDR
0.35
P/S Ratio
LLY
13.16
MNDR
0.42
EV/EBITDA
LLY
27.08
MNDR
0.17

Profitability

Gross Margin
LLY
83.04%
MNDR
19.68%
Operating Margin
LLY
44.9%
MNDR
-22.22%
Profit Margin
LLY
31.67%
MNDR
-35.33%
ROE
LLY
101.16%
MNDR
-47.59%
ROA
LLY
19.41%
MNDR
-23.55%

Growth

Revenue Growth
LLY
42.6%
MNDR
-7.7%
Earnings Growth
LLY
51.4%
MNDR
--

Financial Health

Debt/Equity
LLY
1.65
MNDR
0.01
Current Ratio
LLY
1.58
MNDR
4.22
Quick Ratio
LLY
0.78
MNDR
2.5

Dividends

Dividend Yield
LLY
0.68%
MNDR
--
Payout Ratio
LLY
26.14%
MNDR
0.0%

AI Verdict

LLY NEUTRAL

LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)
MNDR BEARISH

MNDR presents a classic 'value trap' scenario, where a stable Piotroski F-Score of 5/9 and a strong liquidity position (Current Ratio 4.22) mask a catastrophic operational collapse. Despite negligible debt (D/E 0.01) and low valuation multiples (P/B 0.35), the company is suffering from negative profit margins (-35.33%) and declining revenue growth (-7.70% YoY). The most alarming signal is the price performance, with a 5-year decline of 99.7%, indicating a total loss of investor confidence and a failing business model.

Strengths
Very low debt-to-equity ratio (0.01)
Strong short-term liquidity (Current Ratio 4.22)
Low Price-to-Book ratio (0.35) suggesting deep discount to assets
Risks
Severe long-term price erosion (-99.7% over 5 years)
Negative profitability (Profit Margin -35.33%, ROE -47.59%)
Negative revenue growth (-7.70% YoY)

Compare Another Pair

LLY vs MNDR: Head-to-Head Comparison

This page compares Eli Lilly and Company (LLY) and Mobile-health Network Solutions (MNDR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile